New Hampshire Emerging Technologies Caucus

Fostering Innovation, Collaboration, and Progress

← Back to All Events

The Longevity Economy Coming to New Hampshire

Monday, November 3, 2025 at 3:00 PM
Presenter: Alliance for Longevity Initiatives
Location: Online/Teams

AGENDA

  1. Welcome & Introductions
  2. Presentation by Dylan V. Livingston, founder and CEO, of the Alliance for Longevity Initiatives
  3. Q&A with Legislators
  4. Open mic for legislators to discuss any pro- or anti- emerging tech bill filings for 2026
  5. Closing Remarks

A4LI is a 501(c)(4) nonprofit organization dedicated to advancing legislation and policies that extend healthy human lifespans and promote equitable access to innovative therapies. By collaborating with academics, nonprofits, investors, biotech leaders, and policymakers, A4LI addresses key barriers like insufficient federal funding—less than 1% of the NIH budget for aging research—and regulatory hurdles through advocacy for increased investments, streamlined FDA approvals, and a national healthy life expectancy goal.

Meeting Notes

  • Topic: The Longevity Economy
  • Date: November 3, 2025
  • Time: 10:00 AM – 11:15 AM

Website Updates

Reviewed recent updates to the caucus website at emergingtechnh.org. The website now features detail pages for each meeting, including meeting notes and any slide presentations, all publicly available for transparency and continued learning.

Speaker

Dylan V. Livingston – Founder and CEO, Alliance for Longevity Initiatives (A4LI), 501(c)(4) nonprofit organization

Meeting Overview

Dylan provided a comprehensive presentation on the longevity economy and A4LI's mission to advance legislation supporting healthy human lifespan extension through biotech innovation.

Key Presentation Topics

  • Mission Statement: A4LI focuses on advancing legislation for healthy human lifespan with equitable access to next-generation therapeutics, with primary emphasis on longevity biotech.

  • Hallmarks of Aging: Dylan outlined 9-12 identified hallmarks of aging dysfunctions, including senescent (zombie) cells, that have downstream effects on age-related diseases like cancer, inflammation, and frailty.

  • Healthspan vs. Lifespan: The organization prioritizes extending healthspan (years of healthy, functional life), which naturally extends lifespan as a secondary benefit.

  • The Longevity Dividend: Extended healthspan creates economic benefits through reduced healthcare costs (potentially hundreds of billions to trillions) and increased economic productivity from older workers remaining active. Google search

  • A4LI's Role: Acts as conduit between academia, industry, and policymakers (Congress, state legislatures, executive agencies).

Congressional & State Initiatives

  • Longevity Science Caucus: 6 members in U.S. House of Representatives (bipartisan).

  • Montana Model (Right to Try Expansion): Dylan explained Montana's 2023 bill expanding Right to Try Act eligibility to healthy and chronically ill patients (not just terminally ill). The 2024 bill SB 535 operationalizes this with state infrastructure, standards, and liability protections. This creates opportunities for experimental longevity treatments in the U.S. rather than forcing Americans to travel internationally.

  • New Hampshire Opportunity: Similar legislation is being developed with Rep. Kessel Ring. This could position NH as a leading jurisdiction for longevity research and attract biotech companies, particularly leveraging proximity to Boston's biotech ecosystem.

Key Questions & Discussion Highlights

Healthspan vs. Lifespan (Rep. Ammon)

Dylan clarified that A4LI focuses on extending healthspan (quality of life), though extended healthspan naturally results in extended lifespan. The primary driver is economic: healthier people remain economically productive longer, reducing healthcare burden while expanding GDP.

Telomeres & Lifespan Limits (Rep. Ammon)

Telomeres are one of nine hallmarks of aging. The current theoretical lifespan limit is approximately 120 years. Dylan discussed emerging technologies (stem cells, epigenetic reprogramming, organ transplantation) that may extend this limit, but the primary goal is maximizing healthy life within natural limits.

Healthcare Access & Equity (Rep. McAleer)

Rep. McAleer raised concerns about inequitable access creating increased Medicare costs if only some populations benefit. Dylan acknowledged this as a parallel policy issue independent of longevity drug development. He sees longevity therapeutics as potentially solving healthcare inequity through a "silver bullet" approach—drugs that prevent multiple age-related diseases simultaneously.

Multi-Drug Combinations (Rep. Woods)

Dylan clarified that while some researchers pursue single-intervention cures, most longevity treatments will likely require combinations of drugs targeting different hallmarks of aging (senolytics, mitochondrial dysfunction treatments, proteostasis drugs, DNA repair drugs, etc.). Cost discussion: early therapeutics will be expensive, but costs decrease as demand increases and technology matures, similar to cell phone democratization.

Healthcare Cost Savings (Rep. Spahr)

Rep. Spahr noted that end-of-life costs ($80K-$155K per person) would be "shifted, not eliminated." Dylan countered that shifting costly years later in life, when people are economically productive, creates net savings: fewer years burdened by disease versus more years contributing to economy.

End-of-Life Acceptance (Rep. Harvey-Bolia & Rep. Leon)

Discussion on whether extended healthspan enables people to gracefully accept death later in life. Dylan expressed personal conviction to fight aging regardless, while acknowledging others may make different choices. Emphasized optionality: preventing involuntary aging while preserving choice for those ready to "check out."

Economic Productivity Definition (Rep. Cormen)

Economic productivity includes not just paid work but all societal participation: volunteering, consuming goods/services, creating legislation, attending events. Key distinction: participating in economy vs. withdrawing to hospitals/care facilities.

Workforce & Social Disruption (Rep. Woods)

Concern raised about whether economy can accommodate extended workforce participation. Dylan acknowledged aging demographics requiring older workers due to declining birth rates. Referenced convergence of exponential trends (AI, longevity, robotics) making future economic models uncertain. Emphasized life extension as priority; societal restructuring decisions needed after drugs approved.

Longevity Escape Velocity (Rep. Ammon & Dylan)

Discussion of Aubrey de Grey's concept: if science extends lifespan by 1+ years annually, people achieve "escape velocity"—perpetual life extension through successive innovations. Dylan confirmed this is theoretically possible but on ambitious timeline requiring prioritized policy and funding.

Regulatory Structure (Rep. Leon)

Rep. Leon asked whether experimental centers should remain within DHHS or become independent entities. Dylan deferred to legislators, noting traditional DHHS may move slowly but brings valuable oversight perspective. Structure TBD pending New Hampshire's approach.

Peptide Therapy (Rep. Ammon)

Dylan confirmed peptides (including GLP-1s like Ozempic) are legitimate longevity therapeutics—arguably the only current approved longevity drug category. Cautioned that peptide market has bad actors; consumers should work with trusted providers, not "jungle clinics." Called for clinical study of peptides as longevity modality.

Attendees

  • Rep. Keith Ammon
  • Rep. J D Bernardy
  • Rep. Thomas Cormen
  • Rep. Rick Devoid
  • Rep. Tanya Donnelly
  • Rep. Juliet Harvey-Bolia
  • Rep. Brian Labrie
  • Rep. Erica Leon
  • Rep. Chris McAleer
  • Rep. Terry Spahr
  • Rep. Gary Woods
  • Ian Huyett (joined at approx. 10:50 AM)

Action Items

  • Dylan to send contact information and resources: Recommended scientists (Aubrey de Grey, David Sinclair, Matt Kaberline) and TAME trial information for future reference.

  • Coordinate scientist speaker: Dylan offered to arrange a leading longevity scientist to present to caucus in 2-3 months for deep-dive biology education.

  • Legislative bill tracking: Rep. Ammon piloting AI analysis of ~1,000 bills to identify emerging tech legislation. Refined analysis and bill list to be shared with caucus for discussion and support consideration.

  • Create meeting notes: Rep. Ammon will process transcript through AI to generate meeting notes, publish on emergingtechnh.org for transparency and institutional memory.

Next Meeting

Timeline: 3-4 weeks (mid-November 2025)

Topic: Energy (nuclear fusion or battery technology)

Format: Possible field trip to Commonwealth Fusion Systems (MA) facility, or presentation format if logistics prohibit travel

Potential Guest: Sam Evans-Brown (Clean Energy New Hampshire) to discuss leading-edge battery and energy storage technology

Caucus Communication

Group email: emergingtechnh@gaggle.email

Members are encouraged to suggest future topics, speakers, and ideas via this email list.

Generated by K.A. using Claude.ai